Comparison of the antiplatelet and antithrombotic effects of bivalirudin versus unfractionated heparin: A platelet substudy of the HEAT PPCI trial.

[1]  K. Vikram,et al.  Comparison of the effects of P2Y12 receptor antagonists on platelet function in patients undergoing primary PCI: a substudy of the HEAT-PPCI trial , 2018 .

[2]  A. Kastrati,et al.  Bivalirudin versus unfractionated heparin during percutaneous coronary intervention. , 2008, The New England journal of medicine.

[3]  N. Curzen,et al.  “Short” thrombelastography as a test of platelet reactivity in response to antiplatelet therapy: Validation and reproducibility , 2011, Platelets.

[4]  B. Sobel,et al.  Greater inhibitory effects of bivalirudin compared with unfractionated heparin plus eptifibitide on thrombin-induced platelet activation , 2006, Coronary artery disease.

[5]  N. Curzen,et al.  A novel fifteen minute test for assessment of individual time-dependent clotting responses to aspirin and clopidogrel using modified thrombelastography , 2007, Platelets.

[6]  V. Laux,et al.  Direct thrombin inhibitors, but not the direct factor Xa inhibitor rivaroxaban, increase tissue factor-induced hypercoagulability in vitro and in vivo , 2014, Journal of thrombosis and haemostasis : JTH.

[7]  I. Xanthopoulou,et al.  Randomized Assessment of Ticagrelor Versus Prasugrel Antiplatelet Effects in Patients with ST-Segment–Elevation Myocardial Infarction , 2012, Circulation. Cardiovascular interventions.

[8]  B. Sobel,et al.  Decreased Platelet Reactivity in Blood Anticoagulated with Bivalirudin or Enoxaparin Compared with Unfractionated Heparin: Implications for Coronary Intervention , 2002, Journal of Thrombosis and Thrombolysis.

[9]  Mike Fisher,et al.  Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEAT-PPCI): an open-label, single centre, randomised controlled trial , 2014, The Lancet.

[10]  J. Saucedo,et al.  Inhibition of platelet aggregation with eptifibatide, bivalirudin, and heparin in patients undergoing percutaneous coronary intervention receiving clopidogrel pretreatment (The PharmacoDynamic Evaluation of Angiomax, Clopidogrel with or without INtegrilin [DEACON] study). , 2005, The American journal of cardiology.

[11]  Kenichi A. Tanaka,et al.  Thrombin Generation Assay and Viscoelastic Coagulation Monitors Demonstrate Differences in the Mode of Thrombin Inhibition Between Unfractionated Heparin and Bivalirudin , 2007, Anesthesia and analgesia.

[12]  Helmut Baumgartner,et al.  2014 ESC/EACTS Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous , 2014, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[13]  Kenichi A. Tanaka,et al.  Thrombin-activated thrombelastography for evaluation of thrombin interaction with thrombin inhibitors , 2007, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[14]  H. Gray,et al.  Effect of clopidogrel withdrawal on platelet reactivity and vascular inflammatory biomarkers 1 year after drug-eluting stent implantation: results of the prospective, single-centre CESSATION study , 2011, Heart.

[15]  R. de Caterina,et al.  Bivalirudin for acute coronary syndromes: premises, promises and doubts , 2014, Thrombosis and Haemostasis.

[16]  K. Huber,et al.  Bivalirudin is superior to heparins alone with bailout GP IIb/IIIa inhibitors in patients with ST-segment elevation myocardial infarction transported emergently for primary percutaneous coronary intervention: a pre-specified analysis from the EUROMAX trial , 2014, European heart journal.

[17]  R. Abbate,et al.  Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (Rapid Activity of Platelet Inhibitor Drugs) primary PCI study. , 2013, Journal of the American College of Cardiology.

[18]  E. Antman,et al.  Prasugrel versus clopidogrel in patients with acute coronary syndromes. , 2007, The New England journal of medicine.

[19]  H. White.  Pharmacological and clinical profile of bivalirudin in the treatment of patients with acute coronary syndrome , 2009, Expert opinion on drug metabolism & toxicology.

[20]  B. Dimitrov,et al.  Does the response to aspirin and clopidogrel vary over 6 months in patients with ischemic heart disease? , 2015, Journal of thrombosis and haemostasis : JTH.

[21]  S. Pocock,et al.  Bivalirudin started during emergency transport for primary PCI. , 2013, The New England journal of medicine.

[22]  I. Xanthopoulou,et al.  Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study. , 2012, Journal of the American College of Cardiology.

[23]  Adelaide,et al.  Bivalirudin for patients with acute coronary syndromes. , 2006, The New England journal of medicine.

[24]  A. Kastrati,et al.  Impact of bivalirudin or unfractionated heparin on platelet aggregation in patients pretreated with 600 mg clopidogrel undergoing elective percutaneous coronary intervention. , 2008, European heart journal.

[25]  G. Stone,et al.  Bivalirudin vs heparin with or without tirofiban during primary percutaneous coronary intervention in acute myocardial infarction: the BRIGHT randomized clinical trial. , 2015, JAMA.

[26]  A. Kaider,et al.  Regulation of PAR-1 in patients undergoing percutaneous coronary intervention: effects of unfractionated heparin and bivalirudin. , 2009, European heart journal.

[27]  H. Schultheiss,et al.  Bivalirudin inhibits periprocedural platelet function and tissue factor expression of human smooth muscle cells. , 2013, Cardiovascular therapeutics.

[28]  G. Young,et al.  Differential effects of direct thrombin inhibitors and antithrombin-dependent anticoagulants on the dynamics of clot formation , 2007, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[29]  B. Gersh,et al.  Bivalirudin during primary PCI in acute myocardial infarction. , 2008, The New England journal of medicine.

[30]  T. Lisman,et al.  Bivalirudin is inferior to heparin in preservation of intraoperative autologous blood. , 2012, Thrombosis research.

[31]  T. Shibano,et al.  Antithrombin-independent thrombin inhibitors, but not direct factor Xa inhibitors, enhance thrombin generation in plasma through inhibition of thrombin-thrombomodulin-protein C system , 2011, Thrombosis and Haemostasis.

[32]  D. Dudek,et al.  Acute stent thrombosis after primary percutaneous coronary intervention: insights from the EUROMAX trial (European Ambulance Acute Coronary Syndrome Angiography). , 2015, JACC. Cardiovascular interventions.

[33]  H. Gray,et al.  Personalised antiplatelet therapy in stent thrombosis: observations from the Clopidogrel Resistance in Stent Thrombosis (CREST) registry , 2012, Heart.

[34]  B. Sobel,et al.  Streamlining the design of promising clinical trials: in-vitro testing of antithrombotic regimens and multiple agonists of platelet activation , 2009, Coronary artery disease.

[35]  Cunji Gao,et al.  Heparin promotes platelet responsiveness by potentiating αIIbβ3-mediated outside-in signaling. , 2011, Blood.

[36]  A. Kastrati,et al.  Bivalirudin reduces platelet and monocyte activation after elective percutaneous coronary intervention , 2009, Thrombosis and Haemostasis.

[37]  A. Koster,et al.  Bivalirudin: a review , 2005, Expert opinion on pharmacotherapy.

[38]  J. Kirklin,et al.  Argatroban, bivalirudin, and lepirudin do not decrease clot propagation and strength as effectively as heparin-activated antithrombin in vitro. , 2006, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[39]  M. Chintala,et al.  Differential profiles of thrombin inhibitors (heparin, hirudin, bivalirudin, and dabigatran) in the thrombin generation assay and thromboelastography in vitro , 2013, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[40]  Claes Held,et al.  Ticagrelor versus clopidogrel in patients with acute coronary syndromes. , 2009, The New England journal of medicine.

[41]  H. Hamm,et al.  Dichotomous effects of exposure to bivalirudin in patients undergoing percutaneous coronary intervention on protease-activated receptor-mediated platelet activation , 2013, Journal of Thrombosis and Thrombolysis.

[42]  Jörg Hausleiter,et al.  Abciximab and heparin versus bivalirudin for non-ST-elevation myocardial infarction. , 2011, The New England journal of medicine.

[43]  T. Orfeo,et al.  Influence of bivalirudin on tissue factor-triggered coagulation , 2007, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.